minimal residual disease

BMS

Pharma

BMS bags first FDA approval for CELMoD franchise with Zenbexus

The approval represents a double landmark, as Zenbexus also marks the first new multiple myeloma drug cleared by the FDA based directly on MRD.

Angus Liu Aug 14, 2026 10:09am

topic report

Breakthroughs

Breakthroughs Honorees

Sep 9, 2024 5:01am

Rubber stamp with FDA and medicine - stock photo BetNoireGetty Images

FDA review bodes well for MRD-based myeloma approvals

Apr 10, 2024 11:30am

Examine

FDA weighs another approvable myeloma endpoint. What's at stake?

Apr 9, 2024 9:00am